Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - zonisamide - tablet - zonisamide

Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - zonisamide - tablet - zonisamide

Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - zonisamide - tablet - zonisamide

Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - zonisamide - tablet - zonisamide

Ireland - English - HPRA (Health Products Regulatory Authority)

neuraxpharm ireland limited - zonisamide - tablet - zonisamide

European Union - English - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressants - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

European Union - English - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - midazolam - epilepsy - psycholeptics - treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.for infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

European Union - English - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimethyl fumarate - multiple sclerosis, relapsing-remitting - immunosuppressants - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.